Test Price
2,800 AED✅ Home Collection Available
OPTN Gene Sequencing for ALS Type 12 (ALS12) – Genetic Test in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
- ✓Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited next‑generation sequencing (NGS) workflow, ensuring definitive detection of pathogenic variants in the OPTN gene.
- ✓Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection, available daily 8 AM – 11 PM across Dubai, Abu Dhabi, and the Northern Emirates.
- ✓Clinical Guidance: Telephonic post‑test guidance with a DHA‑licensed genetic counsellor to interpret results and outline next steps.
- ✓Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This test analyses the OPTN gene using next‑generation sequencing (NGS) to diagnose or screen for amyotrophic lateral sclerosis type 12 (ALS12), a hereditary form of motor neuron disease. By identifying pathogenic variants with high precision, it empowers neurologists and geneticists to guide personalised care and family risk assessment.
| Feature | Our Test (OPTN NGS) | Closest Alternative |
|---|---|---|
| Precision | 99.9% analytic sensitivity & specificity for OPTN coding region | Single‑site MLPA only, misses most point mutations |
| Method | NGS with Illumina platform, full gene coverage ±20 bp flanking introns | Sanger sequencing of limited exons (partial coverage) |
| Turnaround | 3–4 weeks with expedited VIP reporting | 6–8 weeks standard processing |
Physician Insight & Safety Protocols
“As a DHA‑licensed Consultant Medical Genetics, I emphasise that OPTN gene testing provides critical diagnostic clarity for ALS12. However, genetic results must always be interpreted in conjunction with clinical and family history. I strongly recommend pre‑ and post‑test genetic counselling to fully understand the implications for you and your family.”
— Lina Osama Zaki Quteineh, DHA Registration ID: 9294403
Medication Advisory
Do not discontinue prescribed medication or alter your treatment plan without consulting your doctor. This test is for genetic diagnosis only and does not replace ongoing neurological management.
Safety Guidelines & Exclusion Criteria
- Patients under 18 years require legal guardian consent as per Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- Do not schedule the test if you have an active febrile illness; a stable clinical state is preferred.
- If you have received a blood transfusion in the last 90 days, please inform our team to avoid donor DNA interference.
- Emergency Red Flags: immediately seek medical help if you experience rapidly progressive muscle weakness, difficulty breathing, or swallowing difficulties — these symptoms require urgent in‑person evaluation, not solely genetic testing.
Patient FAQ & Clinical Guidance
1. What does a positive OPTN gene test result indicate for my health?
A positive OPTN test confirms the presence of a pathogenic mutation linked to ALS type 12, guiding precise neurological surveillance and family risk stratification.
2. Is home sample collection available and how is the sample handled?
Our ISO‑certified phlebotomists collect blood samples at your door using cold‑chain transport that preserves DNA integrity until laboratory processing. VIP Mobile Phlebotomy is available daily from 8 AM to 11 PM.
3. Can this test predict the age of onset or severity of ALS12?
Genetic testing identifies the mutation but cannot predict exact onset or progression; clinical monitoring remains essential for timely intervention.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance
This service fully complies with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Our laboratory holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | OPTN Gene Sequencing (ALS Type 12) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral Whole Blood |
| Methodology Used | Next‑Generation Sequencing (NGS) – Illumina Platform, full gene coverage including ±20 bp flanking introns |
| ICD-10-CM Code | G12.2 (Motor neuron disease, other) |
| LOINC Code | 94646-4 (Neurological disorders gene mutations detected) |
| DHA Facility License & Laboratory Address | DHA License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians